Loading
Esophageal Cancer Research and Treatment · Journal article
Current Issues in Molecular Biology · August 16, 2026
Raises a question worth testing. It does not answer one.
This mini-review examines the current state of host-microbiome integration in esophageal cancer, concluding that mechanistic understanding (particularly the Lactobacillus salivarius–indole-3-lactic acid–AhR/NF-κB axis) has progressed substantially, but clinical predictive integration remains premature and impeded by methodological and analytical limitations. The authors call for prospective, multicenter, longitudinal studies with compartment-matched sampling and external validation to determine whether microbial features improve treatment selection beyond existing biomarkers.
Journal article. Patients with esophageal cancer receiving immune checkpoint inhibitors or undergoing treatment.
Mechanistic studies identified Lactobacillus salivarius-indole-3-lactic acid-AhR/NF-κB axis as driving CD8-positive T-cell exhaustion and resistance to anti-PD-1 therapy Tissue studies reveal compartment-specific relationships between microbial diversity or taxa and immune architecture Treatment cohorts identify bacterial and fungal signatures associated with pathological or immunotherapy response
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that microbiome-derived biomarkers are not yet ready for treatment guidance in esophageal cancer. Future clinical utility depends on prospective validation in well-powered, multicenter cohorts with harmonized sampling and analysis protocols.
This is a narrative mini-review synthesizing mechanistic and observational evidence on host-microbiome integration in esophageal cancer, but it does not present primary data, clinical trial results, or validation in a prospective cohort; it identifies research gaps and raises questions rather than answering them.
Clinicians should recognize that microbiome-derived biomarkers are not yet ready for treatment guidance in esophageal cancer. Future clinical utility depends on prospective validation in well-powered, multicenter cohorts with harmonized sampling and analysis protocols.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Immune checkpoint inhibitors have improved outcomes in esophageal cancer across settings, yet clinical benefit remains heterogeneous, with current host-derived biomarkers incompletely predicting response. This mini review evaluates recent studies that integrate gut or intratumoral microbial features with host immune, molecular, or metabolic assessment in esophageal cancer. We classify the evidence using a four-level hierarchy of host-microbiome integration: ecological association, functional association, mechanistic integration, and clinical predictive integration. Tissue studies reveal compartment-specific relationships between microbial diversity or individual taxa and immune architecture, whereas treatment cohorts identify bacterial and fungal signatures associated with pathological or immunotherapy response. Mechanistic studies offer the strongest biological evidence, most notably the Lactobacillus salivarius-indole-3-lactic acid-AhR/NF-κB axis, which drives CD8-positive T-cell exhaustion and resistance to anti-PD-1 therapy. However, biological integration is substantially more advanced than clinical response prediction. Small cohorts, heterogeneous regimens, contamination of low-biomass samples, coarse taxonomic (rather than functional) resolution, confounding by histology, multi-omic layers measured in different patients, and lack of external validation currently jeopardize integration of microbiome to guide treatment. Future studies should use longitudinal, multicenter, compartment-matched sampling and test whether microbial genes or metabolites improve patient selection and predict clinical response beyond established clinical and host biomarkers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.